Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
BIOD's Cash to Debt is ranked higher than
88% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. BIOD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
BIOD' s Cash to Debt Range Over the Past 10 Years
Min: No Debt  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
BIOD's Interest Coverage is ranked higher than
80% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIOD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
BIOD' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: -3.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -66.93
BIOD's ROE (%) is ranked lower than
71% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. BIOD: -66.93 )
Ranked among companies with meaningful ROE (%) only.
BIOD' s ROE (%) Range Over the Past 10 Years
Min: -102.66  Med: -60.46 Max: -34.65
Current: -66.93
-102.66
-34.65
ROA (%) -61.74
BIOD's ROA (%) is ranked lower than
76% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. BIOD: -61.74 )
Ranked among companies with meaningful ROA (%) only.
BIOD' s ROA (%) Range Over the Past 10 Years
Min: -83.02  Med: -49.19 Max: -28.58
Current: -61.74
-83.02
-28.58
ROC (Joel Greenblatt) (%) -5490.83
BIOD's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. BIOD: -5490.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIOD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5195.01  Med: -1586.39 Max: -401.87
Current: -5490.83
-5195.01
-401.87
EBITDA Growth (3Y)(%) -36.10
BIOD's EBITDA Growth (3Y)(%) is ranked lower than
87% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. BIOD: -36.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BIOD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.2  Med: -23.50 Max: 51.6
Current: -36.1
-47.2
51.6
EPS Growth (3Y)(%) -37.90
BIOD's EPS Growth (3Y)(%) is ranked lower than
86% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. BIOD: -37.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BIOD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -44  Med: -28.75 Max: 44.6
Current: -37.9
-44
44.6
» BIOD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

BIOD Guru Trades in Q4 2014

Jim Simons 180,755 sh (+185.55%)
Chuck Royce Sold Out
» More
Q1 2015

BIOD Guru Trades in Q1 2015

Jim Simons 486,884 sh (+169.36%)
» More
Q2 2015

BIOD Guru Trades in Q2 2015

Jim Simons 607,900 sh (+24.86%)
» More
Q3 2015

BIOD Guru Trades in Q3 2015

Jim Simons 572,200 sh (-5.87%)
» More
» Details

Insider Trades

Latest Guru Trades with BIOD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.43
BIOD's P/B is ranked higher than
98% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. BIOD: 0.43 )
Ranked among companies with meaningful P/B only.
BIOD' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 3.3
Current: 0.43
0
3.3
EV-to-EBIT 1.19
BIOD's EV-to-EBIT is ranked higher than
88% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 20.72 vs. BIOD: 1.19 )
Ranked among companies with meaningful EV-to-EBIT only.
BIOD' s EV-to-EBIT Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 1.28
Current: 1.19
0
1.28
EV-to-EBITDA 1.21
BIOD's EV-to-EBITDA is ranked higher than
88% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 18.13 vs. BIOD: 1.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIOD' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 1.3
Current: 1.21
0
1.3
Current Ratio 22.74
BIOD's Current Ratio is ranked higher than
91% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. BIOD: 22.74 )
Ranked among companies with meaningful Current Ratio only.
BIOD' s Current Ratio Range Over the Past 10 Years
Min: 0.82  Med: 11.92 Max: 22.74
Current: 22.74
0.82
22.74
Quick Ratio 22.74
BIOD's Quick Ratio is ranked higher than
92% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. BIOD: 22.74 )
Ranked among companies with meaningful Quick Ratio only.
BIOD' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 11.92 Max: 22.74
Current: 22.74
0.82
22.74

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.43
BIOD's Price/Net Cash is ranked higher than
100% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. BIOD: 0.43 )
Ranked among companies with meaningful Price/Net Cash only.
BIOD' s Price/Net Cash Range Over the Past 10 Years
Min: 0.61  Med: 1.76 Max: 6.86
Current: 0.43
0.61
6.86
Price/Net Current Asset Value 0.43
BIOD's Price/Net Current Asset Value is ranked higher than
99% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 7.24 vs. BIOD: 0.43 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BIOD' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.6  Med: 1.74 Max: 6.67
Current: 0.43
0.6
6.67
Price/Tangible Book 0.42
BIOD's Price/Tangible Book is ranked higher than
99% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. BIOD: 0.42 )
Ranked among companies with meaningful Price/Tangible Book only.
BIOD' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.56  Med: 1.69 Max: 5.82
Current: 0.42
0.56
5.82
Earnings Yield (Greenblatt) (%) 84.26
BIOD's Earnings Yield (Greenblatt) (%) is ranked higher than
96% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. BIOD: 84.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIOD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -3953.54  Med: 0.00 Max: 5045.8
Current: 84.26
-3953.54
5045.8

More Statistics

EPS $ -0.55
Beta1.11
Short Percentage of Float1.45%
52-Week Range $0.22 - 1.54
Shares Outstanding(Mil)64.15

Analyst Estimate

Sep16 Sep17 Sep18
Revenue(Mil)
EPS($) -0.47 -0.79 -0.84
EPS without NRI($) -0.47 -0.79 -0.84

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BDQN.Germany,
Biodel Inc was incorporated in the State of Delaware on December 3, 2003 and commenced operations in January 2004. The Company is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that might be safer, more effective and more convenient for patients. The Company develops its product candidates by applying proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. Its most advanced program involves developing proprietary formulations of injectable recombinant human insulin, or RHI, designed to be more rapid-acting than the 'rapid-acting' mealtime insulin analogs currently used to treat patients with Type 1 and Type 2 diabetes. In addition to its ultra-rapid-acting insulin formulation program, the Company is developing a liquid glucagon formulation for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The FDA and other federal, state, local and foreign regulatory agencies impose substantial requirements upon the clinical development, approval, labeling, manufacture, marketing and distribution of drug products.
» More Articles for BIOD

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jan 29 2016
Biodel Announces Restructuring Update Jan 29 2016
BIODEL INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities Jan 27 2016
3 Biotech Stocks Under $10 to Trade for Big Gains Jan 15 2016
Biodel to Report Fourth Quarter and Fiscal Year 2015 Financial Results on December 17, 2015 Jan 01 2016
Biodel Reports Fourth Quarter and Fiscal Year 2015 Financial Results Jan 01 2016
BIODEL INC Financials Dec 29 2015
Auris Medical Holding (EARS) Looks Good: Stock Up 23.8% Dec 28 2015
BIODEL INC Files SEC form 10-K, Annual Report Dec 22 2015
Biodel downgraded by Ladenburg Thalmann Dec 18 2015
4 Stocks Under $10 Showing Great Upside Today Dec 18 2015
BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition Dec 17 2015
Biodel Reports Fourth Quarter and Fiscal Year 2015 Financial Results Dec 17 2015
Q4 2015 Biodel Inc Earnings Release - 4:00 pm ET Dec 17 2015
Biodel to Report Fourth Quarter and Fiscal Year 2015 Financial Results on December 17, 2015 Dec 14 2015
Biodel Announces Clinical and Corporate Updates Dec 01 2015
What Do Hedge Funds Think of EnteroMedics Inc (ETRM)? Nov 27 2015
Do Hedge Funds Love AEterna Zentaris Inc. (USA) (AEZS)? Nov 24 2015
AEterna Zentaris Inc. (USA) (AEZS) Making Another Monster Move Today Nov 24 2015
BIODEL INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities Nov 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK